Drug intelligence / Profile preview

APOBEC 3A inhibitor

Development stage: Preclinical
Lead developer: Apobec Discovery
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

APOBEC 3A inhibitor is a preclinical-stage small molecule inhibitor developed by Apobec Discovery. It is designed to selectively target and inhibit the DNA dC->dU-editing enzyme APOBEC-3A (APOBEC3A), a cytidine deaminase that converts cytosine to uracil in single-stranded DNA. Dysregulation and overexpression of APOBEC3A drive somatic mutagenesis, tumor evolution, and treatment resistance in various cancers. By blocking APOBEC3A activity, this therapeutic candidate aims to limit cancer-driving mutational activity and prevent the development of drug resistance in oncology indications.

Other names: APOBEC3A inhibitorAPOBEC-3A inhibitorAPOBEC 3A inhibitor

Targets

APOBEC3B (Apolipoprotein B mRNA editing enzyme catalytic subunit 3B)

Beyond the preview

Go deeper on APOBEC 3A inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APOBEC 3A inhibitor.

Explore the full profile